NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company developing brain-penetrant therapeutics for central nervous system (CNS) cancers, today announced newly ...
Making Every Meeting Count: A Qualitative Investigation of Multiteam Meeting Events and Their Role in Supporting Coordinated Cancer Care Delivery Patients with MBC and CNS metastases were eligible for ...
A new nationwide study has revealed striking differences in how brain and nervous system cancers affect Americans depending ...
Variational AI’s Enki™ generative AI platform designed novel ATR/mTOR dual inhibitors with brain penetrance and activity in ...
Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB) Patients were ...
The data we're presenting at CTAD highlights two critical aspects of successful Alzheimer's drug development,” said Jim Doherty, PhD, President and Chief Development Officer of Acumen Pharmaceuticals.
As the brain ages, cells in the central nervous system experience metabolic dysfunction and increased oxidative damage. These ...
- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback